Home
report store
systemic sclerosis epidemiology forecast

systemic-sclerosis-epidemiology-forecast-report

Systemic Sclerosis Epidemiology Forecast - 2036

Published Date : 2026

Pages : 60

Region : United States,

Summary
TOC Table of Content
LOT
- Sample Request

Systemic Sclerosis Epidemiology

Systemic sclerosis affects approximately 100,000 people in the United States, representing about one-third of individuals with scleroderma. It is a chronic, multisystem disease requiring ongoing rheumatologic care, often with input from other medical specialties.
Systemic sclerosis has a highly variable presentation, ranging from limited to diffuse disease with potentially severe lung, vascular, gastrointestinal, and renal complications; early symptoms such as Raynaud phenomenon and puffy fingers may precede diagnosis.
Systemic sclerosis is associated with high autoantibody prevalence, with antinuclear antibodies present in ≥90% of cases and disease-specific anticentromere, anti-RNA polymerase III, and anti-Scl-70 antibodies in up to 70%; genetic and environmental factors may contribute to disease development.
The disease predominantly affects females, with women accounting for approximately 80% of patients, while disease severity and organ involvement can vary according to sex, age, disease subtype, and autoantibody profile.
Diagnosis of systemic sclerosis requires a multidisciplinary assessment of clinical features, disease-specific autoantibodies, nailfold capillaroscopy, and internal-organ involvement, as early and heterogeneous presentations can lead to underdiagnosis and treatment delays.

Systemic Sclerosis Epidemiology Forecast in the 7MM

2025 Diagnosed Prevalent Cases of Systemic Sclerosis: ~232,400
2036 Projected Diagnosed Prevalent Cases of Systemic Sclerosis: ~XXX
Systemic Sclerosis Growth Rate (2026–2036): ~0.5% CAGR

DelveInsight's ‘Systemic Sclerosis – Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the systemic sclerosis, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Study Period	2022–2036
Historical Year	2022–2025
Forecast Period	2026–2036
Base Year	2026
Geographies Covered	North America : The US; Europe: Germany, France, Italy, and Spain and the UK; Asia-Pacific: Japan;
Systemic Sclerosis Epidemiology CAGR (Forecast period)	~0.5% (2026–2036)
Systemic Sclerosis Epidemiology Segmentation Analysis	Patient Burden Assessment Systemic Sclerosis Total Diagnosed Prevalent Cases Systemic Sclerosis Disease Subset-specific Diagnosed Prevalent Cases Systemic Sclerosis Age-specific Diagnosed Prevalent Cases Systemic Sclerosis Organ Involvement-specific Diagnosed Prevalent Cases Systemic Sclerosis Severity by Organ Damage Diagnosed Prevalent Cases Systemic Sclerosis Severity by Skin Thickness Diagnosed Prevalent Cases Systemic Sclerosis Treated Cases

Systemic Sclerosis Understanding and Diagnosis Algorithm

Systemic Sclerosis Overview and Diagnosis

Systemic Sclerosis is a chronic, multisystem autoimmune disorder characterized by immune dysregulation, small-vessel vasculopathy, and progressive fibrosis of the skin and internal organs. The disease is clinically heterogeneous and broadly classified into limited cutaneous and diffuse cutaneous systemic sclerosis, with manifestations ranging from Raynaud phenomenon and skin thickening to severe interstitial lung disease, pulmonary arterial hypertension, gastrointestinal involvement, and scleroderma renal crisis. Disease development is associated with genetic susceptibility, environmental triggers, vascular injury, and dysregulated immune and fibrotic pathways.

Further details are provided in the report.

Systemic Sclerosis Diagnosis

The diagnosis of systemic sclerosis is based on a comprehensive clinical assessment supported by disease-specific autoantibody testing, nailfold capillaroscopy, and evaluation of internal-organ involvement, as no single diagnostic test definitively confirms the disease. The 2013 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) classification criteria incorporate skin thickening, fingertip lesions, abnormal nailfold capillaries, pulmonary arterial hypertension or interstitial lung disease, Raynaud phenomenon, and Systemic Sclerosis-associated autoantibodies. Anticentromere, anti-topoisomerase I, and anti-RNA polymerase III antibodies provide important diagnostic and prognostic information, while pulmonary function testing, high-resolution computed tomography, echocardiography, and other organ assessments help identify clinically significant internal-organ involvement.

Further details are provided in the report.

Systemic Sclerosis Epidemiology

Key Findings from Systemic Sclerosis Epidemiological Analysis and Forecast

As per DelveInsight's analyst, the diagnosed prevalent cases of systemic sclerosis in the 7MM were estimated to be ~ 232,400 cases in 2025.
Among EU4 and the UK, Italy had the highest number (~8%) of diagnosed prevalent cases of systemic sclerosis, while Spain had the lowest number of diagnosed prevalent cases.
Among the age-specific cases, 40–69 age group (~60%) had the highest prevalent cases in the US followed by 70 and above in 2025.
In the US, mild organ damage cases of systemic sclerosis was found to be more as compared to moderate and severe organ damage cases in 2025.
According to DelveInsight estimates, the majority of systemic sclerosis cases in the US are classified as limited cutaneous systemic sclerosis, accounting for approximately 65% of the total cases in 2025, making it the most prevalent subtype compared to diffuse cutaneous systemic sclerosis and systemic sclerosis sine scleroderma.
In EU4 and the UK had nearly 81,000 cases of systemic sclerosis in 2025.
The prevalence of Systemic Sclerosis is estimated at approximately 10–30 cases per 100,000 individuals worldwide, although reported estimates vary substantially across countries because of differences in diagnostic criteria, case ascertainment, and healthcare access.

Scope of the Report

The report covers a segment of a descriptive overview of systemic sclerosis, explaining their causes, signs and symptoms, and pathogenesis.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Systemic Sclerosis Patient Population Forecast

Report Key Strengths

Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
11-year Forecast
Patient Burden Trends (by geography)

FAQs

What are the disease risks, burdens, and unmet needs of systemic sclerosis? What will be the growth opportunities across the 7MM concerning the patient population with systemic sclerosis?
What is the historical and forecasted systemic sclerosis patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges

1 Key Insights

2 Report Introduction

3 Executive Summary

4 Epidemiology Methodology of Systemic Sclerosis

5 Systemic Sclerosis Epidemiology Overview at a Glance

5.1 Patient Share (%) Distribution by Country in 2025 in the 7MM

5.2 Patient Share (%) Distribution by Country in 2036 in the 7MM

6 Disease Background And Overview of Systemic Sclerosis

6.1 Introduction

6.2 Causes

6.3 Signs And Symptoms

6.4 Diagnosis

6.4.1 Differential Diagnosis

6.4.2 Diagnostic Algorithm

6.4.3 Diagnostic Guidelines

7 Epidemiology and Patient Population of Systemic Sclerosis

7.1 Key Findings

7.2 Assumption and Rationale

7.3 Systemic Sclerosis Total Diagnosed Prevalent Cases in the 7MM

7.4 The United States

7.4.1 Systemic Sclerosis Total Diagnosed Prevalent Cases in the United States

7.4.2 Systemic Sclerosis Disease Subset-specific Diagnosed Prevalent Cases in the United States

7.4.3 Systemic Sclerosis Age-specific Diagnosed Prevalent Cases in the United States

7.4.4 Systemic Sclerosis Organ Involvement-specific Diagnosed Prevalent Cases in the United States

7.4.5 Systemic Sclerosis Severity by Organ Damage Diagnosed Prevalent Cases in the United States

7.4.6 Systemic Sclerosis Severity by Skin Thickness Diagnosed Prevalent Cases in the United States

7.4.7 Systemic Sclerosis Treated Cases in the United States

7.5 EU4 and the UK

7.5.1 Systemic Sclerosis Total Diagnosed Prevalent Cases in EU4 and the UK

7.5.2 Systemic Sclerosis Disease Subset-specific Diagnosed Prevalent Cases in EU4 and the UK

7.5.3 Systemic Sclerosis Age-specific Diagnosed Prevalent Cases in EU4 and the UK

7.5.4 Systemic Sclerosis Organ Involvement-specific Diagnosed Prevalent Cases in EU4 and the UK

7.5.5 Systemic Sclerosis Severity by Organ Damage Diagnosed Prevalent Cases in EU4 and the UK

7.5.6 Systemic Sclerosis Severity by Skin Thickness Diagnosed Prevalent Cases in EU4 and the UK

7.5.7 Systemic Sclerosis Treated Cases in EU4 and the UK

7.6 Japan

7.6.1 Systemic Sclerosis Total Diagnosed Prevalent Cases in Japan

7.6.2 Systemic Sclerosis Disease Subset-specific Diagnosed Prevalent Cases in Japan

7.6.3 Systemic Sclerosis Age-specific Diagnosed Prevalent Cases in Japan

7.6.4 Systemic Sclerosis Organ Involvement-specific Diagnosed Prevalent Cases in Japan

7.6.5 Systemic Sclerosis Severity by Organ Damage Diagnosed Prevalent Cases in Japan

7.6.6 Systemic Sclerosis Severity by Skin Thickness Diagnosed Prevalent Cases in Japan

7.6.7 Systemic Sclerosis Treated Cases in EU4 and the UK

8 Patient Jounery of Systemic Sclerosis

9 KOL Views of Systemic Sclerosis

10 Appendix

10.1 Bibliography

10.2 Report Methodology

11 DelveInsight Capabilities

12 Disclaimer

13 About DelveInsight

List of Tables:

List of Tables

Table 1: Systemic Sclerosis Epidemiology in 7MM (2022-2036)

Table 2: Systemic Sclerosis Diagnosed and Treatable Cases in 7MM (2022-2036)

Table 3: Systemic Sclerosis Epidemiology in the United States (2022-2036)

Table 4: Systemic Sclerosis Diagnosed and Treatable Cases in the United States (2022-2036)

Table 5: Systemic Sclerosis Epidemiology in Germany (2022-2036)

Table 6: Systemic Sclerosis Diagnosed and Treatable Cases in Germany (2022-2036)

Table 7: Systemic Sclerosis Epidemiology in France (2022-2036)

Table 8: Systemic Sclerosis Diagnosed and Treatable Cases in France (2022-2036)

Table 9: Systemic Sclerosis Epidemiology in Italy (2022-2036)

Table 10: Systemic Sclerosis Diagnosed and Treatable Cases in Italy (2022-2036)

Table 11: Systemic Sclerosis Epidemiology in Spain (2022-2036)

Table 12: Systemic Sclerosis Diagnosed and Treatable Cases in Spain (2022-2036)

Table 13: Systemic Sclerosis Epidemiology in the United Kingdom (2022-2036)

Table 14: Systemic Sclerosis Diagnosed and Treatable Cases in the United Kingdom (2022-2036)

Table 15: Systemic Sclerosis Epidemiology in Japan (2022-2036)

Table 16: Systemic Sclerosis Diagnosed and Treatable Cases in Japan (2022-2036)

List of Figures:

List of Figures

Figure 1 Systemic Sclerosis Epidemiology in 7MM (2022-2036)

Figure 2 Systemic Sclerosis Diagnosed and Treatable Cases in 7MM (2022-2036)

Figure 3 Systemic Sclerosis Epidemiology in the United States (2022-2036)

Figure 4 Systemic Sclerosis Diagnosed and Treatable Cases in the United States (2022-2036)

Figure 5 Systemic Sclerosis Epidemiology in Germany (2022-2036)

Figure 6 Systemic Sclerosis Diagnosed and Treatable Cases in Germany (2022-2036)

Figure 7 Systemic Sclerosis Epidemiology in France (2022-2036)

Figure 8 Systemic Sclerosis Diagnosed and Treatable Cases in France (2022-2036)

Figure 9 Systemic Sclerosis Epidemiology in Italy (2022-2036)

Figure 10 Systemic Sclerosis Diagnosed and Treatable Cases in Italy (2022-2036)

Figure 11 Systemic Sclerosis Epidemiology in Spain (2022-2036)

Figure 12 Systemic Sclerosis Diagnosed and Treatable Cases in Spain (2022-2036)

Figure 13 Systemic Sclerosis Epidemiology in the United Kingdom (2022-2036)

Figure 14 Systemic Sclerosis Diagnosed and Treatable Cases in the United Kingdom (2022-2036)

Figure 15 Systemic Sclerosis Epidemiology in Japan (2022-2036)

Figure 16 Systemic Sclerosis Diagnosed and Treatable Cases in Japan (2022-2036)

*The table of contents is not exhaustive; will be provided in the final report

Related Reports

Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) - Market Insight, Epidemiology and Market Forecast - 2028

DelveInsight's 'Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.